Page 21 - Output file

Potential Risks of Taking Conventional HRT as Revealed by the WHI Study

The most comprehensive evidence about the risks and benefits of taking hormones Bio-identical

after menopause to prevent disease comes from the Women’s Health Initiative
research program. This research program examined the benefits of menopausal (Also known as Body-identical)
hormones on women’s health.

The WHI research program involved two studies - the use of conjugated
oestrogens plus progestin for women with a uterus and the use of conjugated Hormones
oestrogens alone for women without a uterus. In both hormone therapy studies,
women were randomly assigned to receive either the hormone medication being

studied or the placebo.

The WHI conjugated oestrogens plus progestin study was stopped in July 2002, A More Natural Approach
when investigators reported that the overall risks of conjugated oestrogens plus

progestin outweighed the benefits. The news made headlines around the world.
Ultimately, the study showed an increased risk of breast cancer, heart disease,
stroke and blood clots. However, the risk of colorectal cancer and hip fractures was
lower on HRT than those on placebo.

A subgroup of women in the WHI research program participated in the WHI
Memory study. This showed that conjugated oestrogens plus progestin doubled the
risk for developing dementia in postmenopausal women age 65 and older. The risk

increased for all types of dementia, including Alzheimer’s disease.

The WHI conjugated oestrogens alone study, was stopped in February 2004, when
the researchers concluded that conjugated oestrogens alone increase the risk of

stroke and blood clots.

The risk of breast cancer on oestrogen decreased in comparison to women on
placebo. Similar to the results of oestrogen plus progestin, oestrogen alone

decreased the risk of urinary incontinence and showed a decreased risk of hip
fractures.

The Australian Menopause Centre 20 The Australian Menopause Centre 21